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Solution structure of the Hop 
TPRはA domain and investigation 
of target druggability by NMR┸ 
biochemical and in silico 
approaches
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Heat shock protein ぶね ゅHspぶねょ is a molecular chaperone that plays an important role in tumour biology 
by promoting the stabilisation and activity of oncogenic ╅client╆ proteins┻ Inhibition of Hspぶね by 
small┽molecule drugs┸ acting via its ATP hydrolysis site┸ has shown promise as a molecularly targeted 
cancer therapy┻ Owing to the importance of Hop and other tetratricopeptide repeat ゅTPRょ┽containing 
cochaperones in regulating Hspぶね activity┸ the Hspぶね┽TPR domain interface is an alternative site for 
inhibitors┸ which could result in eプects distinct from ATP site binders┻ The TPR binding site of Hspぶね 
cochaperones includes a shallow┸ positively charged groove that poses a signiボcant challenge for 
druggability┻ Herein┸ we report the apo┸ solution┽state structure of Hop TPRはA which enables this 
target for NMR┽based screening approaches┻ We have designed prototype TPR ligands that mimic 
key native ╅carboxylate clamp╆ interactions between Hspぶね and its TPR cochaperones and show that 
they block binding between Hop TPRはA and the Hspぶね C┽terminal MEEVD peptide┻ We conボrm direct 
TPR┽binding of these ligands by mapping のH‒のひN HSQC chemical shift perturbations to our new NMR 
structure┻ Our work provides a novel structure┸ a thorough assessment of druggability and robust 
screening approaches that may oプer a potential route┸ albeit diポcult┸ to address the chemically 
challenging nature of the Hop TPRはA target┸ with relevance to other TPR domain interactors┻
he Hsp90 molecular chaperone has been the target of many clinical and pre-clinical drug discovery programmes 
in the pharmaceutical industry and academic  laboratories1–3. his focus on Hsp90 has been stimulated by its 
unusual and versatile role as a key hub protein that supports and enables the activities of a wide range of ‘cli-
ent’ proteins involved in cellular homeostasis, many of which are oncogenic in  nature4. Targeting Hsp90 with 
small-molecule inhibitors of the ATP hydrolysis site has been shown in early clinical trials to be a promising 
approach to cancer treatment mediated via the simultaneous depletion or inactivation of several oncogenic ‘cli-
ent’ proteins that rely on Hsp90 for their stability or  activity5. In some cases, particularly breast and lung cancer, 
this therapeutic activity is attributed to depletion of single client oncoprotein, such as ampliied HER2 or mutant 
EGFR or ALK, to which the cancers are  addicted6,7. Also thought to contribute to the therapeutic efectiveness 
of Hsp90 inhibitors is that they block a second, broader role of Hsp90 in maintaining cellular proteostasis. his 
role is particularly important under conditions of high levels of protein production in cancer cells and potentially 
also in the hypoxic tumour  microenvironment1. Despite their promise, no Hsp90 inhibitor has been  approved8. 
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One limitation is thought to be that most Hsp90 inhibitors activate the heat shock response, mediated by Heat 
Shock Factor 1 (HSF1), which protects cancer cells from the efects of Hsp90  inhibition9. hus, other approaches 
to target the function of Hsp90 are of  interest10,11.
he ability of Hsp90 to act as a diverse and multi-purposed hub requires a signiicant number of accessory 
or regulatory cochaperone  proteins12. hese cochaperone proteins interact with Hsp90 and its complexes in a 
variety of ways. Amongst these, the largest cochaperone group contains a common tetratricopeptide repeat (TPR) 
domain that binds to a distinct MEEVD sequence at the C-terminus of  Hsp9013. his group of TPR cochaperones 
act as both regulators and scafolds for Hsp90  activity14. here are over 20 known or suspected TPR cochaperones 
currently listed in the Hsp90 Interactors  resource15, including a series of high molecular weight immunophilins 
(Cyp40, FKBP51 and FKBP52), the protein phosphatase 5 (PP5), and the E3 ubiquitin ligase CHIP, as well as 
many  more16–18.
In the present paper we explore one well-known and biologically important TPR cochaperone of Hsp90, 
namely the Hsp70/Hsp90-organising protein (Hop). Hop is a scafolding protein that allows client transfer from 
Hsp70 to Hsp90 complexes and which also prevents ATP hydrolysis by Hsp90 to encourage a ‘client-ready’ Hsp90 
 conformation19,20. Structurally, Hop contains three TPR domains—TPR1, TPR2A and TPR2B—together with 
two aspartate and proline rich (DP1 and DP2)  domains21. Hsp90ƍs C-terminal MEEVD sequence is the primary 
interaction site with the Hop TPR2A  domain22. his highly conserved sequence is used as an anchor between 
Hsp90 and many of its TPR cochaperones. he interaction is formed between the acidic residues in the MEEVD 
peptide and basic residues in a groove of the TPR binding site, dubbed the carboxylate clamp (Supplementary 
Fig. S1). he importance of the carboxylate clamp has been demonstrated through mutagenesis of Hop TPR2A 
and Hsp90 MEEVD residues and subsequent determination of the dissociation  constants22.
Structural and functional studies have established a series of secondary interactions between Hsp90 and Hop, 
revealing a complex picture of client loading and Hsp90  stabilisation23. Following docking between the Hsp90 
C-terminal MEEVD sequence and TPR2A, the Hop protein engages with the C-terminal and middle domains of 
Hsp90 via both the TPR2A and TPR2B  domains24. he adjacent DP2 domain of Hop does not appear to interact 
directly with Hsp90 but is critical for the activation of speciic clients, perhaps through direct client-Hop protein 
 interactions25. he Hop TPR1 domain engages with Hsp70ƍs C-terminal IEEVD sequence, analogous to Hsp90 
and TPR2A, allowing coordinated client transfer from Hsp70 to Hsp90. During this transfer the Hop DP1 domain 
is thought to play an additional role in client stabilisation. hese varied interactions allow Hop to stabilise open, 
client-ready conformations of Hsp90 and slow ATP  hydrolysis19. In addition to this well studied molecular role 
in client transfer, Hop has also been linked to a variety of other biological efects including HSF1 transcriptional 
activity, tumour cell invasion and endothelial cell polarisation and  migration26–28, perhaps suggesting particular 
downstream biological roles for this cochaperone.
he initial promise and subsequent limitations of drugs targeted to the Hsp90 ATP site has stimulated sig-
niicant interest in alternative mechanisms to target chaperones or afect heat shock  pathways3. For example, 
proteins such as Hsp70 and HSF1 have also been proposed as potential drug  targets29–32. In addition to these, 
small-molecule inhibitors of the protein–protein interactions (PPIs) between Hsp90 and its cochaperones, such 
as Hop, would enable further dissection of Hsp90 biology and could lead to drugs that act as modulators of 
Hsp90-inhibitor activity or as speciic inhibitors of particular elements of Hsp90 function. Such inhibitors could 
therefore induce biological efects that are distinct from ATP site Hsp90 inhibitors and hence result in potential 
therapeutic advantages. his is evidenced by the recent discovery and characterization of small-molecules that 
inhibit the interaction between Hsp90 and its cochaperone  Cdc3733.
Despite the biological rationale behind targeting TPR domains of Hsp90 cochaperones, there are very few 
chemical tools available to test such therapeutic hypotheses. Cyclic peptidic compounds based on Sansalvamide 
A, a marine natural product depsipeptide, were shown to block secondary TPR cochaperone-Hsp90 interactions 
by binding to a hydrophobic site between the N-terminal and middle domains of  Hsp9034. Linear peptides that 
mimic key features of Hsp90-binding TPR domains may also have the ability to prevent Hsp90-Hop associa-
tion in cells and cause the depletion of Hsp90  clients35. Following these discoveries, cyclised TPR peptides were 
shown to interact directly with the C-terminal MEEVD of Hsp90 and reduce TPR cochaperone association with 
 Hsp9036,37. Beyond peptidic inhibitors, attempts to identify small-molecule inhibitors targeting the Hop TPR2A 
domain by high-throughput screening (HTS) have yielded a series of toxolavin-based  inhibitors38,39. However, 
these toxolavins are compromised in their usefulness by being ubiquitous ‘frequent hitters’ in HTS campaigns 
as well as very toxic to  cells40–43. More recently, a structurally related chemical series of thiol-reactive acrylamide-
containing compounds has also been  published44. hese compounds do not bind Hsp90 or its cochaperones, but 
exert their activity through intracellular thiol oxidation. Again, the promiscuous nature of these compounds 
makes them poorly suited for use as chemical biology tools or leads. he overall lack of more promising chemi-
cal matter probably relates to the shallow, charged nature of the Hop TPR2A-Hsp90 MEEVD interface, and 
emphasizes the importance of taking new approaches to identify TPR ligands.
Our current understanding of Hsp90 biology and the development of targeted therapeutics has been greatly 
enabled by small-molecule inhibitors of Hsp90, oten originating from natural products, acting as chemical 
 tools45. Attempting to progress towards chemical tools that inhibit Hsp90-cochaperone interactions is justiied 
since it could ofer similar beneits in chaperone research and drug discovery. In the present work we rigorously 
investigate the druggability of Hop TPR2A and provide clear evidence conirming the challenging nature of this 
target. In addition, we report the complete NMR resonance assignments of Hop TPR2A and provide a high-
resolution solution structure that has potential to provide a foundation for future NMR-based investigation of 
this protein. Ater carrying out HTS and fragment screening campaigns that failed to identify promising Hop 
TPR2A domain binders, we took inspiration from the native carboxylate clamp interaction to design a focused 
in silico screen. Using biochemical assays we show that compounds we identiied through this hypothesis-driven 
computational approach do indeed block the Hop TPR2A-Hsp90 interaction in vitro and we provide robust 
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orthogonal conirmation of target binding with protein-detected NMR-based screening. his approach, combined 
with our site-speciic resonance assignments, allowed us to map the ligand binding sites on Hop TPR2A, con-
irming mimicry of the carboxylate clamp mechanism, and to determine ligand binding ainity. Hence, we have 
provided a new approach for ligand discovery against a hard-to-drug Hsp90-TPR interaction target. We conclude 
that further progress would require a sustained and focused efort to identify tool compounds, which may be 
justiied because Hsp90-TPR interactions present a set of biologically attractive targets owing to their functional 
importance and wide prevalence. However, we caution that such a campaign would be very challenging.
Results and discussion
NMR solution structure of the Hop TPRはA domain┻ We expressed Hop TPR2A in uniform 15N,13C-
labelled form and carried out a full assignment of backbone and side-chain resonances (see “Methods”). Using 
these assignments we determined the high resolution NMR structure of the Hop TPR2A domain, residues 220–
350 (~ 16 kDa), in the absence of the cognate Hsp90 peptide ligand (PDB:2NC9; see Fig. 1 and structural statis-
tics in Supplementary Table S1). Despite being independently generated, the structure relects the well-known 
TPR fold seen in previous X-ray crystal and solution structures of similar Hsp90-binding domains.
Interestingly, our new structure shows that the Hop TPR2A domain is, in solution, fully folded in the absence 
of its Hsp90 binding partner and is highly similar to the X-ray crystal structure of Hop TPR2A co-crystallised 
with the Hsp90 C-terminus (Supplementary Fig. S2)21. Calculating the electrostatic potential of the solvent-
exposed surface of this domain (Fig. 1c) highlights the positively charged peptide-binding groove. his groove 
is complementary to the strongly negatively charged Hsp90 C-terminal peptide, which contains four carboxylic 
acid groups.
he Hop TPR2A construct used in the present study was highly stable during extended experimentation at 
35 °C. his stability, the excellent dispersion of amide signals and the ring-current shited methyl groups we 
observed in the NMR spectra (Supplementary Fig. S3)—along with the similarity of the X-ray (complexed) and 
NMR (free) structures—show unequivocally that the tertiary structure of Hop TPR2A is present in the apo state. 
hese data indicate that Hop TPR2A does not undergo concerted folding and binding in the presence of the 
Hsp90 peptide MEEVD in the same manner as another TPR-containing Hsp90 cochaperone  PP546. However, 
the many chemical shit changes we observed in 1H–15N HSQC spectra upon binding of the small, hydrophilic 
Hsp90 peptide MEEVD (Supplementary Fig. S4a and vide infra) are somewhat surprising given the remarkable 
similarity of the free and bound structures. Hence, we cannot rule out that there is a change of conformational 
dynamics upon ligand binding that is not apparent from the structures of the free and/or bound states. hese 
two structures will tend to relect a static (X-ray) or time-averaged (conventionally-determined NMR) picture 
respectively, neither of which incorporate information about dynamic conformational changes that may be 
occurring in solution.
Computational analysis of druggability┻ he nature of the shallow, positively charged groove which 
makes up the Hop TPR2A binding site together with the lack of TPR domain ligands identiied to date suggests 
that Hop TPR2A is likely to be at best a borderline druggable target. Using our canSAR  platform47,48, we carried 
out a computational analysis of the druggability of the interfaces for 13 Hsp70/Hsp90-TPR structures compris-
ing eight distinct complexes (see full list in Supplementary Table S2). While PPIs are typically challenging for 
small-molecule inhibition, assessment through canSAR is able to shed light on more promising druggable cavi-
Figure 1.  NMR structures of the Hop TPR2A domain rotated 90° around the x-axis. (a) Ensemble views of 
the inal 20 NMR models. (b) Ribbon representation of the ensemble average. (c) Electrostatic potential of 
the solvent-accessible surface calculated with the adaptive Poisson-Boltzmann solver (APBS) PyMol plug-in. 
Surface is coloured from − 10 kT/e negative charge in red to + 10 kT/e positive charge in blue. he strongly 
positively charged groove of Hop TPR2A is clearly deined.
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ties. canSAR contains assessments of > 118,000 structures of complexes containing > 646,000 PPI interface cavi-
ties; approximately 80,000 of these cavities are rated as highly druggable.
We found that none of the 13 TPR domain structures inspected were predicted to be druggable using standard 
small-molecule druggability criteria from the canSAR knowledgebase. he Hop TPR2A-Hsp90 MEEVD inter-
action consists of a fairly large peptide-protein binding interface, calculated to be ~ 532 Å2 using the published 
crystal structure of the  complex21. Within this large interface, the canSAR methodology identiied three cavities 
(Supplementary Fig. S5a-c). he enclosure of the best cavity falls just within the boundary of strict druggabil-
ity criteria—e.g. as would be expected for the ATP-binding sites of protein kinases (Supplementary Fig. S5d). 
Moreover, the enclosure falls comfortably within the values observed for druggable PPIs, such as that of Bcl-2 
(Supplementary Fig. S5d and Supplementary Table S3). he same pattern is observed for hydrophobic/polar 
group ratios (Supplementary Fig. S5e).
However, when considering other key parameters such as the enclosed volume and the energetic contribution 
quantiied using the Inverse Andrews’ Energy  measure49,50, we ind that the distribution of all Hop cavities falls 
outside the strict druggability criteria, and only barely overlaps with the distribution of druggable PPI values 
(Supplementary Fig. S5f,g and Supplementary Table S3). he best Hop TPR2A cavity falls at the low range limit 
of Bcl-2 and kinase ATP site cavities.
Crucially, clusters of positively charged groups within the Hop TPR2A binding site add to the druggability 
challenge. Comparison with a well-established druggable PPI (the venetoclax binding site of Bcl-2) shows the 
diferences in the electrostatic potential distribution between the strongly positively charged Hop surface and 
the mixed positive, negative, and neutral character of the Bcl-2 surface (Supplementary Fig. S6). his signii-
cant positively charged surface of Hop TPR2A would require acidic compounds to complement it. Such acidic 
compounds can pose challenges for progression to drug-like molecules due to poor membrane  permeability51.
In summary, the enclosure of the best identiied Hop TPR2A binding cavity approaches the druggable range 
for PPIs. Yet, the volume of the cavity and lower predicted binding energy point to it being a challenging target. 
Importantly, the presence of a signiicantly positively charged groove on the protein surface demonstrates a 
need for highly acidic complementary compounds, which will be very challenging to progress to drugs. Over-
all, the low druggability and the structural features of the Hop TPR2A-Hsp90 MEEVD interface indicate the 
scale of the challenge to inding useful small-molecule ligands and chemical tools. A regularly updated, full 
assessment of druggability for all available Hop structures deposited in the PDB can be accessed at the canSAR 
 knowledgebase52.
Unbiased small┽molecule and fragment screening approaches┻ In view of the challenge and in 
order to give the best chance of success, we decided that it would be appropriate to take several orthogonal 
approaches to identify small-molecule ligands. Initially, we carried out a biochemical HTS using over 80,000 
compounds from our structurally diverse Cancer Research UK Cancer herapeutics Unit compound library. 
his library has previously generated progressible hits against multiple molecular targets. We measured the 
efects of compounds on the interaction between biotin-labelled Hsp90 MEEVD peptide and Hop TPR2A 
using an AlphaScreen assay similar to that previously published (see Supplementary Methods, Supplementary 
Table S4 and  reference39). his approach did not generate any high-quality hit matter that could be progressed 
owing to high numbers of false positive hits. hese false positives were identiied through counter-screens of 
hit compounds using assays such as Amplex Red for the detection of redox active  compounds53. False positives 
included compounds the apparent activity of which could not be conirmed in secondary biochemical assays, 
such as the LANCE assay discussed below. In addition, we also used the biochemical AlphaScreen assay to evalu-
ate a library of 2000 fragment-like compounds, at a concentration of 400 μM against the Hop TPR2A domain. 
Once again no true hits were identiied.
Ligand┽directed approach to carboxylate clamp binders┻ he lack of hits from the unbiased HTS 
and fragment screening campaigns prompted us to take a ligand-directed approach to identifying chemical 
starting points for Hop TPR2A-Hsp90 interaction inhibitors. he interaction between Hsp90 and many of its 
TPR cochaperones relies upon a carboxylate clamp, where a series of hydrogen bonds anchor the carboxylic 
acids in the Hsp90 MEEVD peptide into the positively charged Hop TPR2A binding groove (Supplementary 
Fig. S1)21. Compounds containing succinic acid substructures were therefore selected to mimic the natural car-
boxylate clamp interaction between the Hsp90 C-terminus and TPR cochaperones. he ability of these com-
pounds to disrupt the interaction between a short Hsp90 MEEVD peptide and Hop TPR2A was investigated 
using a TR-FRET-based biochemical LANCE proximity assay (see “Methods”). In this assay, compounds that 
block the protein-peptide interaction cause a loss in luorescent signal.
Starting with succinic acid, 1, a series of simple diacids were tested for activity in the LANCE assay (Table 1). 
Promisingly, succinic acid itself was a weak inhibitor of the Hop TPR2A-Hsp90 MEEVD interaction with an 
IC50 of ~ 4 mM. his was an encouraging proof of concept for the ability of small fragments to replicate the 
carboxylate clamp interaction and displace the Hsp90 peptide. Various restraints to the relative orientation of 
the two acids were introduced to determine if there was an optimal presentation for binding. he orientation 
of the two acids in a cis conformation was preferred to trans when comparing compounds 2 and 3. he ring 
constrained conformation of 4 was preferred to the unconstrained conformation of 1. However, the  IC50 changes 
across compounds 1–4 were only a few fold in magnitude, suggesting there was not a strong preference in acid 
orientation for Hop TPR2A binding. We attempted to further develop these small diacid-containing compounds 
by exploring changes to the linker and attached substituents. In total an additional 40 compounds were assayed 
of which a representative selection is shown in Table 1 (1–6). Overall these changes led to only minor improve-
ments in potency and did not maintain the ligand eiciency of the succinic (1) and maleic (2) acids.
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Having demonstrated that compounds selected to replicate the clamp contacts were active in our biochemical 
assay, we built on this proof of concept by performing a focused in silico docking screen of commercially available 
compounds containing the succinic acid substructure. We reasoned that by sampling a chemical subspace that 
retained the succinic acid substructure we could enhance inhibitor potency over that seen for the simple diacids 
discussed above and identify novel interactions to exploit in further inhibitor development.
To achieve this, we performed a substructure search on a collection of > 4 million commercially available 
compounds via the eMolecules  website54. For the succinic acid substructure this yielded 155 unique, non-peptidic 
molecules which were each docked into the Hsp90 MEEVD peptide binding site of Hop TPR2A (PDB:1ELR) 
using  Glide55. Here, we were looking for molecules that were able to maintain the carboxylate clamp interac-
tions whilst simultaneously forming additional contacts such as mimicking hydrophobic contacts formed by the 
valine of the MEEVD peptide. We inspected the docking results and selected 14 compounds, based on visual 
assessment of the docked poses, for purchase and biochemical testing using the LANCE assay referred to above.
Out of these 14 compounds we identiied one compound, 7 (Fig. 2a), that demonstrated increased LANCE 
biochemical activity over the simple diacids. his compound was based on a tryptoline scafold and had an  IC50 
of 74 μM in the LANCE assay (Fig. 2b). Docking poses of the lowest energy binding modes of 7 generated dur-
ing the in silico screen suggested a binding orientation to one side of the central peptide-binding channel. New 
hydrophobic contacts were made to Hop TPR2A that are not seen in the native peptide-protein interaction, close 
to the backbone of the helix consisting of residues 298–308 (Fig. 2c). We pursued these tryptoline-type com-
pounds when we found compound 8 to be active in our LANCE assay (Fig. 2). Compound 8 is a close analogue 
of 7, but with only a single carboxylic acid group. Highly charged functional groups such as carboxylic acids are 
potentially problematic for cell-membrane penetration and so this modiication was preferable with respect to 
potential probe  inhibitors56,57.
he activity of a series of the tryptoline compounds is detailed in Table 2. We were able to remove the amide 
linker between the acid side-chain and phenyl ring to maintain the aryl carboxylic acid at  R2. Variation of the 
ring position of substituent  R1 in compounds 9–12 showed a preference for the meta and ortho positions with 
 IC50 values of 80 and 94 μM, in comparison to 234 and 452 μM for the para and unsubstituted compounds, 
respectively. Changing the position of the carboxylic acid at  R2 from ortho to para resulted in a more than tenfold 
drop in activity for compound 13 compared to 11. As expected, substitution of the carboxylic acid, compound 
14, caused a complete loss of activity. hese structure–activity relationships (SARs) suggest that both the car-
boxylic acid and hydrophobic contacts seen in the docked model of 7 are important for Hop TPR2A binding by 
this series of ligands. However, the solubility of compound 14 is likely to be low in comparison to the rest of the 
series, which could contribute to its apparent complete lack of activity.
Conボrmation of ligand binding by NMR chemical shift perturbation ゅCSPょ┻ Our identiication of 
the tryptoline series of compounds demonstrated the potential of the carboxylate mimic approach to inhibitor 
discovery. However, we felt that a further demonstration of ligand binding was necessary to conirm the validity 
of these inhibitors.
Table 1.  Inhibition of Hop TPR2A-Hsp90 MEEVD binding by a representative selection of small diacid-type 
compounds. LANCE  IC50 and ligand eiciency (LE) values are reported (LANCE assay n = 3 independent 
experiments, duplicate wells for each n, Mean ± S.D. reported).
Compound LANCE  IC50 (µM) LE
1 3,957 ± 315 0.42
2 2,173 ± 199 0.47
3 4,899 ± 248 0.40
4 1,345 ± 35.7 0.33
5 885 ± 23.3 0.25
6 1,189 ± 35.2 0.26
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Given the precedent for false positives in our previous non-biased small-molecule and fragment screening 
approaches, we proposed that a biophysical method would be the most efective to show robust, orthogonal con-
irmation of Hop TPR2A-ligand binding. Protein-detected NMR chemical shit perturbations (CSPs) of protein 
resonances measure the efect of ligand binding on the immediate chemical environment of the binding site and 
avoid the ambiguity of an experimental proxy, such as the loss of FRET transfer following peptide displacement. 
Such CSP approaches can also provide useful information about the location of ligand binding sites when used 
in combination with an assigned NMR structure of the target protein, unlike isothermal titration calorimetry 
(ITC) or surface plasmon resonance (SPR).
Using the Hsp90-peptide MEEVD as a model ligand, we demonstrated that ligand binding to Hop TPR2A can 
be clearly detected through CSPs in a 2D 1H–15N HSQC NMR spectrum (Supplementary Fig. S4a). Our previous 
assignment of the solution Hop TPR2A structure allowed the CSPs to be mapped onto the protein surface to 
indicate which residues undergo the largest changes in chemical environment. his CSP mapping also allowed 
comparison of the observed CSPs to the known binding site of the MEEVD peptide (Supplementary Fig. S4b). 
his demonstrated that the majority of larger shits occurred within the MEEVD peptide binding grove and rarely 
towards the C-terminal section of the domain (Supplementary Fig. S4d). Of the key charged residues involved 
in MEEVD binding (Supplementary Fig. S1), ive of these—Asn233, Asn264, Glu271, Gln298, and Asn308—all 
showed adjusted chemical shits (∆δ) > 0.1 ppm. In constrast, three others—Lys229, Lys301, and Arg305—did 
Figure 2.  (a) Chemical structure of hit compound 7, identiied from the in silico screening of commercially 
available diacid-containing compounds, and close analogue compound 8 (b) Representative concentration–
response curves for inhibition of the Hop TPR2A-Hsp90 MEEVD interaction by compounds 7 and 8 with 
 IC50 values denoted in the key (c) In silico docked pose of 7 (coral) against Hop TPR2A (turquoise surface) 
using docking sotware Glide (PDB code: 1ELR). he Hsp90 peptide (grey) is overlaid for comparison. he 
carboxylate clamp and hydrophobic binding regions are indicated.
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not exceed this threshold. his is likely due to the intermolecular interactions occurring at the end of long side 
chains in the case of lysine and arginine, which may not result in a substantial change of the backbone amide 
signal detected in 1H–15N HSQC experiments. In addition, peptide ligand binding on the fast exchange time-
scale allowed the CSPs to be tracked during the titration and the determination of the MEEVD peptide binding 
constant (Supplementary Fig. S4c)58. he calculated  Kd of 7.7 μM was close to previously reported values from 
ITC (11 μM) and SPR (4–7 μM)21,22,59. We noted that the trajectories of our titrated CSPs were linear, suggesting 
that we were observing a single, speciic binding event for the Hsp90 MEEVD  peptide60.
Compounds containing dicarboxylic acid groups are a potential source of assay interference by acting as 
metal chelators, so our biochemically active diacid compounds were counter-screened using the NMR CSP 
approach to conirm their activity. CSPs caused by the titration of compound 4 (Fig. 3a,c) were linear and indi-
cated speciic binding at the carboxylate clamp region as proposed. he top ten largest CSPs contained two of 
the four carboxylate clamp residues, Gln298 and Lys301. Large CSPs were also observed in a cluster at the start 
of the helix adjacent to the carboxylate clamp, and included hr260, Tyr261, hr263 and Asn264. he  Kd value 
calculated for this titration was ~ 3 mM, (Fig. 3b).
he tryptoline series of compounds were also investigated by NMR CSP screening. Titration of 11 (Table 2) 
against Hop TPR2A generated signiicant CSPs (Fig. 4a). Mapping the observed CSPs onto the protein surface of 
Hop TPR2A revealed a well-deined binding site (Fig. 4c). he largest CSPs were clustered into two groups. One 
group, residues 260–268, formed part of the helix along the bottom of the peptide-binding groove; this group 
of shits was similar to CSPs seen for the Hsp90 MEEVD peptide. he second group was centered on the largest 
CSP observed, Arg305, with a ∆δ of 0.38 ppm (see “Methods”), and included residues Lys301, Ala302, Ala304, 
Ile306, Asn308 and Ser309. his group of CSPs is seen as the dark orange region on the right side in Fig. 4c. 
hese particular CSPs are distinct from the changes seen for the MEEVD peptide and correspond in part to the 
modelled binding surface of the tryptoline and phenyl rings in the docked pose of compound 7 (Supplemen-
tary Fig. S7). Large shits outside these two groups were at or close to aromatic side-chains; and are likely to be 
sensitive ring-current shited resonances. We observed that the carboxylate clamp residue with the largest shit 
was Lys301 (∆δ = 0.1 ppm) which was higher than the average CSP but not among the largest shits caused by 
11, perhaps suggesting that the carboxylate clamp is not engaged by 11 in the same manner as for the MEEVD 
peptide. his is not surprising given that 11 contains only a single carboxylate group. However, signiicant CSPs 
were observed at several of the residues that form additional key contacts with the Hsp90 MEEVD peptide, as 
shown in Supplementary Fig. S1 and S2. hese included Asn264 (∆δ = 0.36 ppm), Arg305 (∆δ = 0.38 ppm), and 
Asn308 (∆δ = 0.12 ppm).
Our measured  Kd for the titration of compound 11 was 177 μM (Fig. 4b), relative to a LANCE  IC50 of 80 μM 
(Table 2). For comparison,  Kd curves were collected for compounds 9, 10 and 12, each identical in structure to 
11 except for variation in the position (or lacking) the key methyl group on the  R1 ring that was important for 
LANCE assay potency. he binding ainities determined by NMR showed the same preference for the position 
of the  R1 substitution as the biochemical activity of the compounds (Table 2), giving added conidence that the 
diference in activity between these compounds is due to genuine changes in target interactions.
Table 2.  Inhibition of Hop TPR2A-Hsp90 MEEVD binding by a series of tryptoline-based compounds 
originating from in silico hit 7. LANCE  IC50 and ligand eiciency (LE) values are reported for all compounds. 
he  IC50 value for the Hsp90 MEEVD peptide is shown for reference (LANCE assay n = 3 independent 
experiments, duplicate wells for each n, Mean ± S.D. reported). NMR CSP dissociation constants are reported 
for selected compounds that vary by the position of the  R1 methyl group. Mean ± S.D. for 10 itted residues are 
reported.
 
Compound R1 R2 LANCE  IC50 (µM) LE NMR CSP  Kd (µM)
MEEVD 4.9 ± 0.9 0.18 7.7 ± 1.0
7 m-OMe o-C(O)NHC(COOH)CCOOH 74 ± 3.2 0.13
8 m-OMe o-C(O)NHCCOOH 311 ± 37 0.13
9 - o-COOH 452 ± 14 0.14 1,411 ± 123
10 p-Me o-COOH 234 ± 75 0.15 729 ± 164
11 m–Me o-COOH 80 ± 5.8 0.17 177 ± 13
12 o-Me o-COOH 94 ± 6.4 0.17 352 ± 39
13 m-OMe p-COOH 1,180 ± 118 0.12
14 m–Me o-OEt Inactive
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In addition to using NMR to conirm the binding of diacid and tryptoline compounds to TPR2A, NMR 
CSPs proved extremely useful in orthogonal assessment of hits from our previous biochemical HTS. Using this 
approach, small-molecule hit compounds against Hop TPR2A identiied in our HTS campaign were shown not 
to cause signiicant CSPs. he compounds were excluded from further development as false positives. hese 
included persistent false-positive hits that we were not able to conclusively exclude as hits using any other 
method, including in the Amplex Red assay, thus demonstrating the potential utility of protein-detected NMR 
as a robust counter-screen for the Hop TPR2A target.
he mode of interaction between the TPR domains of cochaperones and the C-terminal peptides of Hsp90 or 
Hsp70 is remarkably conserved. Our analysis of 13 structurally characterized TPR domain-Hsp90/70 interactions 
showed that the TPR structures are highly similar despite diverging sequences (Supplementary Fig. S8 and S9). 
Furthermore, the hydrogen-bond network comprising the carboxylate clamp interactions is also highly conserved 
across almost all of the complexes, even when the contributing amino acids difer (Supplementary Fig. S9 and 
S10). hus, we feel that the development of efective chemical tools capable of blocking the interaction between 
Hop TPR2A and Hsp90 could have a broader impact on the other members of this family. Towards this end, 
we have obtained preliminary, qualitative data suggesting that 11 may disrupt binding of Hop and another TPR 
cochaperone, PP5, from puriied full-length Hsp90 complexes. his efect was observed in a co-immunopre-
cipitation experiment of Hsp90 complexes from HCT116 human colon cancer cells (Supplementary Fig. S11).
Conclusions
Non-biased small-molecule compound library and fragment screening against the biologically important Hop 
TPR2A target, carried out by ourselves here and also by others, has shown that identifying good chemical start-
ing points for ligand development is extremely challenging. his is consistent with the shallow, solvent-exposed 
and strongly positively charged nature of the binding site of Hop TPR2A. In this present work, we show that 
Figure 3.  Conirmation of small diacid 4 binding to the Hop TPR2A domain as determined by NMR chemical 
shit perturbations (CSPs). (a) Section of Hop TPR2A 1H-15 N HSQC spectra with the titration of 3 at 0, 50, 
100, 750, 1,500 and 7,000 μM shaded black, red, orange, yellow, green and blue respectively. (b) CSPs of selected 
residues plotted against the peptide concentration and itted (see “Methods”) to obtain  Kd values. Mean  Kd ± S.D. 
for 10 itted residues was 3.1 ± 0.1 mM. (c) Surface representation of Hop TPR2A coloured by the magnitude of 
backbone amide CSPs at each residue. he Hsp90 peptide (grey) is overlaid for comparison. CSPs (∆δ) below 
0.012 ppm are shown in white and those above 0.072 ppm in orange. Between these cut-ofs CSP values are 
shaded from white to orange. Selected residues are labelled.
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our strategy to mimic the structurally-characterised carboxylate clamp interaction can be a successful alterna-
tive approach to inding TPR ligands. An in silico screen based on this concept led to active ligands displaying 
some early SAR. Moreover, direct binding to Hop TPR2A was conirmed by NMR. While the potency of these 
ligands is relatively low, with  Kd values greater than 100 μM, they nevertheless demonstrate the potential value 
of targeting the carboxylate clamp along with the utility of the experimental techniques used.
hrough our approach of employing protein NMR to study the Hop TPR2A target, we have provided a 
useful solution structure of the protein, supporting the hypothesis that Hop TPR2A is substantially folded in 
the apo state. Furthermore, the resonance assignments allowed us to exploit NMR as an approach to monitor 
and map ligand binding to key interaction regions on Hop TPR2A, conirming that our ligands do exploit the 
native carboxylate clamp interactions but also potentially novel interactions beyond this site. In addition to 
opening rational avenues for chemical tool development for Hop TPR2A, the insights presented here are likely 
to be applicable to most cochaperone-TPR domain interactions with Hsp90 or Hsp70. We anticipate that our 
solution NMR structure, together with the assignments and ligands discovered here, could be useful tools for 
future research into small-molecule TPR-domain interaction inhibitors. We hope that progress to more potent 
binders would enable demonstration of quantitative inhibitory efects on full-length proteins under a variety of 
nucleotide conditions.
However, our experience suggests that further progress towards the development of potent Hsp90-TPR 
domain interaction inhibitors would require a major, dedicated campaign. While deployment of such resources 
may be warranted given the biological importance of Hsp90 and the large number of TPR-cochaperones, we 
recognise that the limited druggability of TPR domains may ultimately preclude the development of high-ainity 
ligands.
Figure 4.  Conirmation of tryptoline compound binding to the Hop TPR2A domain as determined by NMR 
chemical shit perturbations (CSPs). (a) Section of Hop TPR2A 1H–15N HSQC spectra with the titration of 11 
at 0, 50, 100, 750, and 1,500 μM shaded black, orange, yellow, green and blue respectively. (b) CSPs at selected 
residues plotted against the peptide concentration and itted (see “Methods”) to obtain  Kd values. Mean  Kd ± S.D. 
for 10 residues was 177 ± 13 μM. (c) Surface representation of Hop TPR2A coloured by the magnitude of 
backbone amide CSPs at each residue. he Hsp90 peptide (grey) is overlaid for comparison. CSPs (∆δ) below 
0.0375 ppm are shown in white and those above 0.131 ppm in orange. Between these cut-ofs CSP values are 
shaded from white to orange.
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Materials and methods
Druggability assessment┻ Druggability assessment was carried out using a comprehensive suite of sophis-
ticated, orthogonal methodologies utilising machine learning and AI predictions. he tools and methodologies 
used are available at our online canSAR  platform47–49,52.
NMR experiments for assignments and structure calculations┻ NMR experiments were performed 
on samples of 1.5 mM uniformly 15N, 13C-labelled protein in 20 mM  Na2HPO4 pH 6.5, 50 mM NaCl, 1 mM DTT 
with 10%  D2O, protease inhibitors and 0.01%  NaN3. When performing experiments where water signals are 
problematic, e.g. 13C-NOESY-HMQC, the sample was freeze-dried and resuspended in  D2O. Experiments were 
carried out in 5 mm tubes (Sigma-Aldrich) at 35 °C.
Backbone atom assignments were completed with standard HNCACB, CBCA(CO)NH, HNCO and HN(CA)
CO experiments acquired with sparse (20–33%) non-uniform sampling (NUS) in the indirect  dimensions61. 
Aliphatic sidechains were assigned using a combination of HBHA(CBCACO)NH, H(C)CH-TOCSY, (H)CCH-
TOCSY and amide-detected (H)C(CCO)NH- and H(CCCO)NH-TOCSY spectra, acquired using NUS at 
33–40%. Aromatic ring assignments were made from a 13C-NOESY-HMQC spectrum in conjunction with the 
TROSY-1H, 13C-aromatic HSQC and (HB)CB(CGCD)H-TOCSY  experiments62,63. Data were collected on Bruker 
Avance III (600 MHz) and Avance II (800 MHz) spectrometers equipped with TCI and TXI cryoprobes, respec-
tively, controlled by Topspin3 (Bruker Biospin Ltd). Data were processed using  NMRPipe64, with reconstruc-
tion using MDD 2.065, and analysed in NMRView (One Moon Scientiic). Assignment was aided by NMRView 
modules which provided rapid input for MARS automated assignment and facile handling of sidechain  data66.
Constraints for structure calculations were obtained from 3D 1H–15N NOESY-HSQC and 3D 1H–13C NOESY-
HMQC spectra. Backbone φ (phi) and ψ (psi) angles were estimated using the program TALOS + . Together 
with the resonance assignments these data were used for structure calculations using ARIA v2.3 sotware, which 
employs CNS for simulated annealing calculations.
LANCE assay┻ he interaction between His-tagged Hop TPR2A and a biotin-labelled Hsp90 C-terminal 
peptide with the sequence MEEVD was measured using a lanthanide chelate excite (LANCE) assay, a form of 
time resolved Förster resonance energy transfer (TR-FRET) assay. he labelling reagents used were Surelight 
APC-SA and LANCE Eu-1024 Anti-6xHis (both PerkinElmer). Assays were performed in black low volume 
384-well plates (Corning) with a total volume of 20 μl per well in assay bufer of 20 mM HEPES pH 7.4, 100 mM 
NaCl, 1 mM DTT, 0.1% Tween-20. Final assay composition was 250 nM biotin-Hsp90α peptide, 100 nM Hop 
TPR2A, 2 nM Anti-6xHis antibody and 45 nM APC-SA. Compound stocks to be screened were individually 
corrected to approximately neutral pH due to their highly acidic nature and dispensed using a Labcyte Echo 
acoustic dispenser.
Raw luorescence or luminescence values from compound screening were converted to % inhibition of the 
total assay signal.  IC50 values were determined by plotting % inhibition against the  log10 of inhibitor concentration 
and itted using a variable slope, four-parameter concentration–response curve using a robust it in GraphPad 
Prism. Curve maximum was constrained to 100% and minimum to 0% to ensure that the reported  IC50 values 
were at 50% of total signal inhibition. To generate  IC50 values, assays were repeated independently 3 times with 
duplicate or triplicate wells for each run. Final values are reported as the mean and standard deviation of 3 curve 
its. Ligand eiciency (LE) was approximated from LANCE biochemical  IC50 values using the number of heavy 
atoms (HA)67.
In silico screening methods┻ Compounds were prepared for docking using LigPrep (Schrödinger) with 
default settings. Epik (Schrödinger) was used for protonation state assignment and tautomer  generation68. For 
the protein preparation, protons were added to PDB 1ELR using Protonate3D in MOE (Chemical Computing 
Group Inc.). he structure was preprocessed using the Protein Preparation Wizard in Maestro with ‘Assign bond 
orders’, ‘Create disulide bonds’ and ‘Convert selenomethionines to methionines’ options  selected69. Grids for 
Glide docking were then generated using the Receptor Grid Generation tool in Maestro using an ‘Enclosing box’ 
of size 20 Å around the centre of the Hsp90 MEEVD peptide with other settings let at default. he ligands were 
then docked using Glide in SP mode with default settings and the results visualized in  MOE55.
Chemical shift perturbation ゅCSPょ screening using のH‒のひN HSQC spectra┻ Chemical shit pertur-
bation (CSP) experiments were carried out on protein and compound mixtures to characterise protein–ligand 
interactions. 1H-15N HSQC spectra were collected on 200 μl samples in 20 mM  Na2HPO4 pH 6.5, 50 mM NaCl, 
1 mM DTT with 10%  D2O in 3 mm NMR tubes (GPE Scientiic). he Hsp90 peptide used as a ligand had the 
sequence MEEVD and was not acetylated or biotinylated. Each sample was prepared with 100 μM protein while 
compound or peptide concentration varied according to the experiment. Where possible, compound or peptide 
stocks were made up in NMR bufer to minimise bufer efects on the spectra. Compounds were otherwise 
diluted from DMSO stocks maintaining a maximum inal DMSO concentration of 3% v/v. HSQC spectra of the 
protein with DMSO in the bufer were collected as controls. 1H–15N HSQC spectra were collected using standard 
pulse sequences.
Changes in chemical shits (∆δ) were calculated for each backbone assigned N–H peak using a weighted 
 CSP70. In order to visualise the locations of the largest shits the ∆δ values were edited into a Hop TPR2A PDB ile 
(in place of B-factors) and represented as surface heat maps in PyMol.  Kd values from CSP titrations were calcu-
lated from HSQC spectra collected at a series of increasing compound  concentrations58, plots are representative of 
one titration for several diferent residues.  Kd values are averaged from a minimum of 5 residues across two titra-
tions. We provide further information on the CSP curve itting equations used in the Supplementary Methods.
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